Alixorexton

Alixorexton
	File:Alixorexton.svg
Clinical data
Other names	ALKS-2680; ALKS2680
Routes of; administration	Oral
Drug class	Orexin OX2 receptor agonist
Identifiers
	IUPAC name N-[(15S,16R)-10-oxo-8,18-dioxa-11-azatetracyclo[17.2.2.02,7.011,16]tricosa-2,4,6-trien-15-yl]methanesulfonamide;
CAS Number	2648347-56-0;
PubChem CID	156417714;
IUPHAR/BPS	13879;
UNII	3BRW4ARU66;
E number	{{#property:P628}}
CompTox Dashboard (EPA)	{{#property:P3117}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).;
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C21H30N2O5S
Molar mass	422.54 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C1N2CCC[C@@H]([C@@H]2CO[C@@H]3CC[C@@H](CC3)C4=C(OC1)C=CC=C4)NS(=O)(C)=O;
	InChI InChI=InChI=1S/C21H30N2O5S/c1-29(25,26)22-18-6-4-12-23-19(18)13-27-16-10-8-15(9-11-16)17-5-2-3-7-20(17)28-14-21(23)24/h2-3,5,7,15-16,18-19,22H,4,6,8-14H2,1H3/t15?,16?,18-,19-/m0/s1; Key:IHNJMACFBQEKRJ-VHZYLWGESA-N;

Alixorexton (INNTooltip International Nonproprietary Name; developmental code name ALKS-2680) is an orexin receptor agonist which is under development for the treatment of sleep disorders, including narcolepsy and idiopathic hypersomnia.^[1]^[2]^[3] Alixorexton is being developed by Alkermes^[4] As of July 2025, it is in phase 2 clinical trials with planned advancement to a phase 3 study for the treatment of narcolepsy type 1.^[4]

References

^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
^ ^a ^b Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).

Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).

[Morse_2025-2] Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).

[Prakash_2025-3] Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).

[Chen_2025-4] Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).

[1]

[2]

[3]

[4]

v t e Wakefulness-promoting agents
Catecholaminergic agents	Dopamine reuptake inhibitors (DRIs): Adrafinil^‡ Armodafinil Mesocarb^‡ Modafinil Phenylpiracetam (fonturacetam) Norepinephrine reuptake inhibitors (NRIs): Atomoxetine Desipramine Reboxetine Viloxazine Norepinephrine–dopamine reuptake inhibitors (NDRIs): Amineptine^‡ Bupropion Dexmethylphenidate Methylphenidate Nomifensine^‡ Serdexmethylphenidate Solriamfetol Serotonin–norepinephrine–dopamine reuptake inhibitors (SNDRIs): Mazindol Norepinephrine releasing agents (NRAs): Ephedrine Pseudoephedrine Selegiline (via metabolites) Norepinephrine–dopamine releasing agents (NDRAs): Amphetamine Dextroamphetamine Levoamphetamine^‡ Lisdexamfetamine Methamphetamine Mixed amphetamine salts Pemoline^‡
Orexin receptor agonists	Alixorexton^§ Danavorexton^§ Firazorexton^§ Oveporexton^†
Histamine H₃ receptor antagonists	Pitolisant Samelisant^§
Adenosine receptor antagonists	Caffeine Istradefylline Paraxanthine
Others	GABA_A receptor antagonists and negative allosteric modulators (e.g., clarithromycin, flumazenil, pentylenetetrazol (pentetrazol)) GABA_B receptor agonists (e.g., sodium oxybate/γ-hydroxybutyrate (GHB)) (via improved nightly sleep) Nicotinic acetylcholine receptor agonists (e.g., nicotine)
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III
See also: Stimulants List of investigational narcolepsy and hypersomnia drugs

Alixorexton

See also

References

Navigation menu

Search